Ways to keep weight off after stopping GLP-1 weight-loss meds

Who could benefit from this research

What this research studies

If people with obesity stop taking high-dose GLP-1 medications, they often quickly regain weight. The study plans two parallel randomized trials to see if switching to a generic non-GLP-1 weight-management pill or gradually tapering the GLP-1 dose helps prevent weight regain for at least 6 months. Researchers will enroll adults with a history of obesity (with or without type 2 diabetes) who have discontinued GLP-1 therapy and follow them to compare outcomes, safety, and adherence. The goal is to identify practical, real-world strategies that patients can use with doctors to sustain weight loss after stopping GLP-1 treatment.

Why it matters

Where this research is happening

• Massachusetts General Hospital
  Boston, United States Active

Researchers

• Principal investigator: Wexler, Deborah J — Massachusetts General Hospital
• Study coordinator: Wexler, Deborah J

Related research

Other NIH-funded projects on the same topics.

• Understanding how GLP-1 drugs affect energy use in brittle diabetes

  This grant looks at how GLP-1 receptor drugs change how the body handles sugar and fats, beyond lowering blood sugar or appetite, to help people with brittle diabetes.

  NIH research Harvard University D/b/a Harvard School of Public Health · Boston, United States · NIH-11599303

• GLP-1 receptor drugs and heart-brain health in diabetes and Alzheimer’s risk

  A Duke-led study will explore how GLP-1 receptor medicines and exercise affect brain and heart health in models prone to diabetes and Alzheimer’s risk.

  NIH research Duke University · Durham, United States · NIH-11536555

• GLP-1 medicines to improve heart, kidney, and metabolic health for people with HIV and type 2 diabetes

  A real-world study will look at how GLP-1 receptor agonists affect heart and kidney health and lifetime costs for people living with HIV and type 2 diabetes.

  NIH research Boston University Medical Campus · Boston, United States · NIH-11470780

• Lifestyle plan to protect muscle and heart health for adults with obesity using GLP-1 medications

  A real-world trial tests a combined nutrition and resistance-training program versus standard care for adults starting GLP-1 weight loss drugs to preserve lean mass and cardiovascular health.

  NIH research University of Florida · Gainesville, United States · NIH-11452740

• Pre-pregnancy GLP-1 Medication Use and Stopping It: Effects on Blood Sugar and Pregnancy Outcomes

  This project looks at how using GLP-1–based weight loss medicine before pregnancy and stopping it before trying to conceive affects blood sugar and pregnancy health.

  NIH research University of Rochester · Rochester, United States · NIH-11438182

• GLOW-UPS: long-acting vs daily buprenorphine for people leaving prison

  A large study will compare long-acting injectable buprenorphine to daily oral buprenorphine for adults with opioid use disorder who are about to leave prison, to see which keeps people adherent and safe after release.

  NIH research New York University School of Medicine · New York, United States · NIH-11415917

About this research

1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.